Executive Editor, The American Journal of Managed Care
Mary Caffrey is the Executive Editor of The American Journal of Managed Care (AJMC). With a focus on managed care and healthcare delivery, Mary's work covers a wide range of topics including new guidelines in oncology, value-based care, clinical trial data, and the management of various diseases. Her articles provide insights and analysis for healthcare professionals and researchers in the field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Mary Caffrey's coverage predominantly focuses on healthcare and pharmaceuticals, specifically within the field of oncology. Her articles heavily rely on data and press releases, indicating a preference for factual information from credible sources. Sources with access to relevant clinical trial or real-world data could be particularly valuable in reaching out to her.
Given the technical nature of the topics covered, experts who can provide insights into new research findings, medical breakthroughs, or trends within oncology would likely capture Mary's interest.
While she does not have a specific geographic focus, it is essential that pitches are based on substantial scientific evidence and contribute meaningfully to ongoing conversations in oncology and related fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Mary Caffrey
A review of positions and track records of Vice President Kamala Harris and former President Donald Trump on reproductive health, the future of the Affordable Care Act, prescription drug costs, health care consolidation, and a proposed Medicare home health benefit.
By: Laura Joszt, Mary Caffrey
There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.
By: Mary Caffrey
Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end points, with data that show how survival benefits are biologically linked to changes in the spleen, reduction in fibrosis, or other responses.
By: Laura Joszt, Mary Caffrey
Therapy selection for younger patients with myeloproliferative neoplasms (MPNs) may be different based on the desire for fertility preservation, but they are also at greater risk of their disease progressing, explained Ruben Mesa, MD, FACP, of Atrium Health.
By: Mary Caffrey
Being married and having insurance can offer emotional support and financial stability to lead to early diagnosis and effective treatment, the authors found.
By: Mary Caffrey, Laura Joszt
Symptomatic improvement on therapy for myeloproliferative neoplasms (MPNs) is very much based on the individual. Data does show momelotinib not only improved spleen size and anemia but also improved symptomatic burden.
By: Mary Caffrey
Listen Key Takeaways Momelotinib's higher pharmacy costs outweigh its clinical benefits and lower transfusion costs compared with ruxolitinib.
By: Mary Caffrey
Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of the election.
By: Mary Caffrey
Therapies for obesity and inhibitors for lipoprotein(a) (Lp[a]) are among those to be featured at the American Heart Association (AHA) Scientific Sessions November 16-18, 2024, which will take place in Chicago, where the AHA was founded 100 years ago.
By: Mary Caffrey
The key driver in both sets of findings is the relationship between neutrophils and inflammation. The links among NLR, thrombosis, and mortality are seen across the 2 studies. The authors from the PV study concluded:
(833) 317-6278 
